Dr. Vinay Prasad, a notable figure at the Food and Drug Administration (FDA) with a focus on vaccines, is set to depart from the agency at the end of April, as confirmed by a spokesperson from the Department of Health and Human Services.
In his role as chief science and medical officer, Dr. Prasad wielded considerable influence over vaccine-related decisions. His tenure was marked by several contentious choices, including overruling career scientists regarding certain vaccine approvals and taking a firm stance against a biotech company associated with patient harm.
Dr. Prasad’s time at the FDA was not without controversy. Last summer, he faced dismissal following a campaign led by right-wing influencer Laura Loomer. However, after intervention from Dr. Marty Makary, the agency’s commissioner, and Health Secretary Robert F. Kennedy Jr., he was reinstated.
His recent actions have continued to attract scrutiny; he faced backlash for rejecting treatments intended for rare diseases and made headlines for denying Moderna’s application for a new mRNA flu vaccine, a decision that was later overturned by Dr. Makary.
Prior to his appointment at the FDA, Dr. Prasad held an academic position at the University of California, San Francisco, where he was known for his critical stance towards the FDA, arguing that the agency’s drug review process had a low threshold for approval.
He has also been identified as a COVID contrarian, having expressed dissent regarding public health measures he believed were not adequately supported by medical evidence, through various platforms including podcasts and his YouTube channel.
A senior administration official noted that Dr. Prasad had taken a year-long leave from his academic position in California, with intentions to return.
This report was initially published by The New York Times.